公开(公告)号：US20240230622A9

公开(公告)日：2024-07-11

申请号：US18323844

申请日：2023-05-25

申请人： Laboratory Corporation of America Holdings

发明人： Ute Geigenmuller ,  Doris Damian ,  Maciej Pacula ,  Mark A. DePristo ,  Jeffrey R. Luber

IPC分类号： G01N33/49 ,  G01N33/68 ,  G16H50/20 ,  G16H50/30 ,  G16Z99/00

CPC分类号： G01N33/492 ,  G01N33/6896 ,  G16H50/20 ,  G16H50/30 ,  G16Z99/00 ,  G01N2800/28 ,  G01N2800/38

摘要： In certain embodiments, the invention stems from the discovery that analysis of population distribution curves of metabolite levels in blood can be used to facilitate predicting risk of autism spectrum disorder (ASD) and/or to differentiate between ASD and non-ASD developmental delay (DD) in a subject. In certain aspects, information from assessment of the presence, absence, and/or direction (upper or lower) of a tail effect in a metabolite distribution curve is utilized to predict risk of ASD and/or to differentiate between ASD and DD.

公开(公告)号：US20180231572A1

公开(公告)日：2018-08-16

申请号：US15883014

申请日：2018-01-29

申请人： AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.

发明人： Lin Mei ,  Wen-Cheng Xiong ,  Bin Zhang ,  Chengyong Shen

IPC分类号： G01N33/68 ,  C07K16/28 ,  G01N33/92 ,  G01N33/564 ,  C12Q1/6883

CPC分类号： G01N33/6896 ,  C07K16/28 ,  C07K2317/76 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N33/564 ,  G01N33/6893 ,  G01N33/92 ,  G01N2333/705 ,  G01N2500/04 ,  G01N2800/28 ,  G01N2800/38

摘要： The present invention includes methods for the detection of neurotransmission or developmental disorders, including, but not limited to, myasthenia gravis that is seronegative for autoantibodies to the acetylcholine receptor (AChR) and/or muscle specific tyrosine kinase (MuSK), the method including detecting autoantibodies that bind to LRP4, or an epitope thereof. Also included are methods for the treatment of an individual suffering from a neurotransmission disorder, the method including detecting in a bodily fluid of the individual autoantibodies that bind to LRP4, or an epitope thereof, and administering to the patient an effective amount an immunosuppressant and/or another appropriate therapeutic modality. Also included are antibodies that bind to autoantibodies to LRP4 and kits for the detection of neurotransmission or developmental disorders.

公开(公告)号：US20180172686A1

公开(公告)日：2018-06-21

申请号：US15847398

申请日：2017-12-19

申请人： MEDELA HOLDING AG

发明人： Foteini Kakulas

IPC分类号： G01N33/569 ,  G01N33/68

CPC分类号： G01N33/56972 ,  G01N33/569 ,  G01N33/6854 ,  G01N33/6863 ,  G01N2800/38

摘要： The present invention relates to a method for assessing the infection status of a subject and in particular to a method for assessing the infection status of a subject by analysing the cellular and/or humoral composition of breastmilk from said subject. The invention has been developed primarily for use as a method for detecting infection in a breastfeeding mother and/or infant.

公开(公告)号：US09804171B2

公开(公告)日：2017-10-31

申请号：US15045146

申请日：2016-02-16

申请人： Moleculera Labs, Inc. ,  The Board of Regents of the University of Oklahoma ,  National Institutes of Health

发明人： Phina Madeleine Cunningham ,  Craig David Shimasaki ,  Susan E. Swedo ,  Christine Kirvan

IPC分类号： A61K38/00 ,  G01N33/53 ,  G01N33/68 ,  G01N33/564 ,  G01N33/569

CPC分类号： G01N33/686 ,  G01N33/564 ,  G01N33/56944 ,  G01N33/6854 ,  G01N33/6896 ,  G01N2333/315 ,  G01N2333/726 ,  G01N2333/912 ,  G01N2405/10 ,  G01N2469/20 ,  G01N2800/26 ,  G01N2800/28 ,  G01N2800/30 ,  G01N2800/38

摘要： The present invention provides a panel of at least five clinical analyses or tests (using serum samples) to determine the risk of pediatric acute-onset neuropsychiatric syndrome (PANS) and/or pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) in an individual. These include enzyme linked immunosorbent assays (ELISAs) to measure antibody titers against neuronal antigens present in the brain; the neuronal antigens include lysoganglioside, tubulin, dopamine receptor D1, dopamine receptor D2, serotonin receptor 5HT2A, and serotonin receptor 5HT2C. Antibody titers against at least four of these neuronal antigens are required in the present methods; preferably antibody tiers against all of these neuronal antigens are measured. A final assay is used to quantify calcium/calmodulin-dependent protein kinase activity using a neuronal cell line. The results of these analyses or tests are then combined using an algorithm to determine whether a PANS or PANDAS diagnosis is appropriate for the individual. Depending on the diagnosis, an appropriate treatment can be determined.

公开(公告)号：US20170121422A1

公开(公告)日：2017-05-04

申请号：US15300656

申请日：2015-03-31

申请人： UNIVERSITETET I TROMSØ - NORGES ARKTISKE UNIVERSITET ,  UNIVERSITY HOSPITAL OF NORTH NORWAY ,  NORINNOVA TECHNOLOGY TRANSFER AS

发明人： Terje MICHAELSEN ,  Oistein IHLE ,  Tor Brynjar STUGE ,  Anne HUSEBEKK ,  Heidi TILLER ,  Mariana EKSTEEN ,  Bjorn Ragnar SKOGEN

IPC分类号： C07K16/34 ,  G01N33/68

CPC分类号： C07K16/34 ,  C07K16/2848 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/54 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/70 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6893 ,  G01N2333/705 ,  G01N2800/38

摘要： The present invention provides an isolated antibody that specifically binds to HPA-1a. Also provided is a nucleic acid molecule that encodes the antibody, and compositions comprising the antibody. Also provided is a method of producing the antibody and methods and uses which employ the antibody. Also provided are therapeutic uses of the antibody, for example in the treatment or prophylaxis of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

公开(公告)号：US09545397B2

公开(公告)日：2017-01-17

申请号：US14731603

申请日：2015-06-05

申请人： AMICUS THERAPEUTICS, INC.

发明人： Elfrida Benjamin ,  Hung V. Do ,  Xiaoyang Wu ,  John Flanagan ,  Brandon Wustman

IPC分类号： A61K31/445 ,  C07K14/00 ,  G01N33/68 ,  C12Q1/34

CPC分类号： A61K31/445 ,  C07K14/00 ,  C12Q1/34 ,  G01N33/6893 ,  G01N2333/47 ,  G01N2333/94 ,  G01N2800/38 ,  G01N2800/52

摘要： The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining α-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of α-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.

摘要翻译： 本发明提供了确定患有溶酶体储存障碍的患者是否将受益于用特定药物伴侣的治疗的方法。 本发明例举了在表达来自α-半乳糖苷酶A的突变体的细胞系中测定α-半乳糖苷酶A对药物分子伴侣如1-脱氧半乳糖吉非霉素的反应性的体外方法。本发明还提供了一种诊断患者法布里病的方法 怀疑患有法布里病。

公开(公告)号：US20150309053A1

公开(公告)日：2015-10-29

申请号：US14437771

申请日：2013-10-23

申请人： RIKEN ,  NATIONAL UNIVERSITY CORPORATION HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE

发明人： Takeo Yoshikawa ,  Motoko Maekawa ,  Norio Mori ,  Hideo Matsuzaki ,  Kazuhiko Nakamura

IPC分类号： G01N33/68

CPC分类号： G01N33/6896 ,  C12Q1/6883 ,  C12Q2600/156 ,  G01N33/92 ,  G01N2333/47 ,  G01N2800/2814 ,  G01N2800/38 ,  G01N2800/50 ,  G01N2800/7085

摘要： A novel test method for testing for the presence or absence of a predisposition to autistic spectrum disorder or the presence or absence of development of autistic spectrum disorder is provided. The test method includes a test step of determining an amount of at least one of the fatty acid binding proteins FABP3, FABP4, FABP5, and FABP7 in a sample prepared from the living body of a human or determining an expression level of at least one of the FABP3, FABP4, FABP5, and FABP7 genes in the sample.

摘要翻译： 提供了一种新的测试方法，用于测试自闭症谱系障碍的存在或不存在或自闭症谱系障碍发展的存在或不存在。 测试方法包括测定从人的活体制备的样品中至少一种脂肪酸结合蛋白FABP3，FABP4，FABP5和FABP7的量，或确定至少一种 样品中的FABP3，FABP4，FABP5和FABP7基因。

公开(公告)号：US09095584B2

公开(公告)日：2015-08-04

申请号：US14054369

申请日：2013-10-15

申请人： AMICUS THERAPEUTICS

发明人： Elfrida Benjamin ,  Hung V. Do ,  Xiaoyang Wu ,  John Flanagan ,  Brandon Wustman

IPC分类号： A61K31/445 ,  C07K14/00 ,  G01N33/68 ,  C12Q1/34

CPC分类号： A61K31/445 ,  C07K14/00 ,  C12Q1/34 ,  G01N33/6893 ,  G01N2333/47 ,  G01N2333/94 ,  G01N2800/38 ,  G01N2800/52

摘要： The present invention provides methods to determine whether a patient with a lysosomal storage disorder win benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining α-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of α-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.

摘要翻译： 本发明提供了确定患有溶酶体储存障碍的患者是否获益于用特定药物分子伴侣治疗的方法。 本发明例举了在表达来自α-半乳糖苷酶A的突变体的细胞系中测定α-半乳糖苷酶A对药物分子伴侣如1-脱氧半乳糖吉非霉素的反应性的体外方法。本发明还提供了一种诊断患者法布里病的方法 怀疑患有法布里病。

公开(公告)号：US20140308687A1

公开(公告)日：2014-10-16

申请号：US14353969

申请日：2012-10-25

申请人： InfanDx AG

发明人： Matthias Keller ,  David Enot

IPC分类号： G01N33/68 ,  G01N27/447

CPC分类号： G01N33/6896 ,  G01N27/447 ,  G01N2800/28 ,  G01N2800/38 ,  G01N2800/60 ,  G16B20/00 ,  G16C20/70

摘要： Metabolites and signatures (panels) of metabolites are applicable as biomarkers in clinical diagnosis, in particular for neonatal encephalopathy. They are useful tools in differential clinical diagnosis for early detection of brain injury, determination of brain areas affected by the insults and prediction of adverse neurological outcome and may also be applied in diagnosing disease progression and treatment effect. An in vitro method for predicting the likelihood of neonatal encephalopathy of distinct brain areas, identification of affected brain area(s) of neonatal encephalopathy and risk of brain damage and prognosis and neurological outcome due to identification of the type and extent of damage of distinct brain tissues, in particular of hippocampus and/or basal ganglia, is provided.

摘要翻译： 代谢物的代谢物和特征（面板）可用作临床诊断中的生物标志物，特别适用于新生儿脑病。 它们是早期检测脑损伤，确定受侮辱影响的脑区的确定和不良神经学结局预测的有用工具，也可用于诊断疾病进展和治疗效果。 一种用于预测不同脑区新生儿脑病的可能性的体外方法，确定新生儿脑病的脑区面积以及脑损伤风险和预后以及由于识别不同大脑的损伤类型和程度引起的神经学结果 提供组织，特别是海马和/或基底神经节的组织。

公开(公告)号：US20130315990A1

公开(公告)日：2013-11-28

申请号：US13983624

申请日：2012-02-03

申请人： Lars Bode

发明人： Lars Bode

IPC分类号： A61K31/702 ,  A23L1/29 ,  A23K1/16 ,  A61K35/74

CPC分类号： A61K35/742 ,  A23K10/18 ,  A23K20/163 ,  A23K40/10 ,  A23K50/00 ,  A23L5/00 ,  A23L29/30 ,  A23L33/125 ,  A23L33/135 ,  A23L33/40 ,  A23P10/28 ,  A61K31/702 ,  A61K35/741 ,  G01N33/50 ,  G01N2400/00 ,  G01N2800/065 ,  G01N2800/067 ,  G01N2800/38 ,  G01N2800/7095

摘要： The invention provides formulations comprising isolated Disialyllacto-N-tetraose (DSLNT) or variants, isomers, analogs and derivatives thereof.

摘要翻译： 本发明提供了包含分离的二唾液乳糖-N-四糖（DSLNT）或其变体，异构体，类似物和衍生物的制剂。